The Power of SGLT2 Inhibitors to Improve Renal Outcomes in CKD
| Overview / Abstract: |
Target Audience This activity is designed to meet the educational needs of nephrology and primary care providers (physicians, physician assistants, nurse practitioners, nurses, diabetes educators, and pharmacists) and other specialists (cardiology, endocrinology, internal medicine physicians) involved in the care and treatment of patients with chronic kidney disease. Program Overview Chronic kidney disease (CKD) may result from multiple etiologies, including diabetes, hypertension, and various other conditions. Patients with CKD have a significant disease burden, including an increased risk of cardiovascular disease and stroke, anemia, metabolic issues (calcium, phosphorus, potassium abnormalities), kidney failure, and early death. Clinical trials with SGLT2 inhibitors have shown a decrease in the progression of CKD. SGLT2 inhibitors represent a new category of oral antidiabetic agents that can also reduce systolic and diastolic blood pressure, as well as serum uric acid, and improve the glomerular filtration rate. Apart from affecting renal hemodynamics and glycotoxicity, evidence suggests that SGLT2 inhibitors may be renoprotective due to their effects on inflammation in renal tissues. With the expanding use of SGLT2 inhibitors beyond glucose control, this AI-driven activity will inform clinicians about the available evidence assessing their efficacy and safety in CKD, renoprotective benefits in patients with CKD with and without T2DM, evolving practice standards, and their relevance to patient care. Learning Objectives Upon completion of this activity, participants should be better able to: Describe the unmet medical needs associated with cardiovascular, renal and mortality risks in patients with chronic kidney disease (CKD) |
|
Expiration |
Mar 31, 2022 |
|
Discipline(s) |
Nurse Practitioner , Physician CME |
|
Format |
Online |
|
Credits / Hours |
1.0 AMA PRA Category 1 Credit(s)™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Faculty FACULTY_NAME Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. He is supported by the Canadian Institutes of Health Research, the JDRF, the Heart and Stroke Richard Lewar Centre of Excellence, the Heart and Stroke Foundation of Canada and the Banting and Best Diabetes Centre. He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney’s research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR - Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award. FACULTY_NAME Dr. Jennifer Green is a professor of medicine in the division of endocrinology, metabolism, and nutrition at Duke University and a faculty member of the Duke Clinical Research Institute. Her research has focused upon strategies to treat diabetes mellitus and reduce the risk of cardiovascular, renal and other diabetes-related complications. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes). She currently serves as US coordinating center PI and US national representative for the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease. Dr. Green is also a member of the American Diabetes Association’s Professional Practice Committee, which publishes the organization’s annual Standards of Care in Diabetes. for the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease. Dr. Green is also a member of the American Diabetes Association’s Professional Practice Committee, which publishes the organization’s annual Standards of Care in Diabetes. |
|
Sponsors / Supporters / Grant Providers |
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. |
|
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCMe., Renal Free CE CME |
|